GSK has reported the outcomes of its phase 3 clinical testing period for its MenABCWY combination vaccination. They tested to establish whether it created a safe and successful immune response in those aged 10 to 25 when received in two parts, with sixth months between each dose.

The most crucial elements of the evaluation were achieved during the initial stages of testing. The data showed that GSK’s combination vaccine performed at the same level as other treatment options on the market, including Bexsero and Menveo. This data only applies for those in the same age bracket with a satisfactory safety profile.

“GSK’s combination vaccine performed at the same level as other treatment options on the market, including Bexsero and Menveo“

They also reported that the vaccine in question proved to be successful in protecting against 110 different invasive variations of meningococcal disease, 95% of the variations currently found in the US.

If GSK gets this officially signed off, it may be the only vaccine on the market that can protect against that many serogroups, ultimately resulting in a streamlined vaccination schedule.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.